Taxus Cardium Pharmaceuticals Group (CRXM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2015 | 12-2014 | 12-2013 | 12-2012 | 12-2011 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -3,698 | -5,506 | -8,914 | -8,323 | -7,129 |
| Depreciation Amortization | 10 | 14 | 296 | 281 | 195 |
| Accounts receivable | N/A | N/A | 222 | -183 | 0 |
| Accounts payable and accrued liabilities | 586 | 214 | 518 | -182 | 152 |
| Other Working Capital | 1,150 | 365 | 1,593 | -1,311 | -637 |
| Other Operating Activity | 899 | 2,289 | 260 | 505 | -254 |
| Operating Cash Flow | $-1,053 | $-2,624 | $-6,025 | $-9,213 | $-7,674 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | N/A | N/A | -23 | -16 | -4 |
| Net Acquisitions | N/A | N/A | N/A | 288 | N/A |
| Investing Cash Flow | $N/A | $N/A | $-23 | $272 | $-4 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 258 | 688 | N/A | N/A | 0 |
| Common Stock Issued | 600 | N/A | N/A | 1 | 4,530 |
| Other Financing Activity | 0 | 2,130 | 3,743 | 6,546 | 1,225 |
| Financing Cash Flow | $858 | $2,818 | $3,743 | $6,547 | $5,755 |
| Beginning Cash Position | 217 | 23 | 2,328 | 4,721 | 6,644 |
| End Cash Position | 22 | 217 | 23 | 2,328 | 4,721 |
| Net Cash Flow | $-195 | $194 | $-2,306 | $-2,393 | $-1,923 |
| Free Cash Flow | |||||
| Operating Cash Flow | -1,053 | -2,624 | -6,025 | -9,213 | -7,674 |
| Capital Expenditure | N/A | N/A | -23 | -16 | -4 |
| Free Cash Flow | -1,053 | -2,624 | -6,049 | -9,229 | -7,678 |